Floatz logo

Velaglucerase Alfa

Gaucher Disease

Takedaprotein_peptidePhase 4 / ApprovedActive
A
83/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
79/ 100
Competitive Position
89/ 100

Competitive context

5 Active assets in the Gaucher Disease cohort.

Asset / SponsorPhaseRating
Taliglucerase Alfa
Protalix
Phase 4A
.ALPHA.-D-GLUCOSYL-N-ACYLSPHINGOSINE GLUCOHYDROLASE
Sanofi
Phase 4A
Eliglustat
Peking Union Medical College Hospital
Phase 3BBB
Cerezyme® / Imiglucerase
University Hospital, Clermont-Ferrand
Phase 4BBB
ISOFAGOMINE
Amicus Therapeutics
Phase 2BB

View all 28 →

Same molecule, other indications

Velaglucerase Alfa is also rated in:

diseaseDormant
BB
Indicative · Phase 4
69 / 100
View asset →
Gaucher disease type IDormant
BB
Indicative · Phase 4
65 / 100
View asset →
Gaucher disease type IIIDormant
CCC
Indicative · Phase 1/2
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →